3-Week group (n = 10) | 4-Week group (n = 10) | 5-Week group (n = 10) | Control group (n = 10) | P value | |
---|---|---|---|---|---|
Sex (female, n/total n, %) | 9/10, 90% | 9/10, 90% | 8/10, 80% | 8/10, 80% | 0.85 |
Age (years) | 55.3 (14.8) | 65.0 (9.9) | 62.0 (10.6) | 66.7 (11.0) | 0.27 |
RA duration (months) | 101.5 (86.5) | 68.5 (74.6) | 116.5 (92.5) | 81.9 (78.7) | 0.35 |
Tocilizumab duration (months) | 27.1 (20.7) | 11.9 (9.2) | 39.6 (12.1) | - | <0.01* |
RF positive (n, %) | 7/10, 70% | 9/10, 90% | 9/10, 90% | 5/10, 50% | 0.12 |
ACPA positive (n, %) | 5/8, 63% | 7/10, 70% | 8/10, 80% | 6/10, 60% | 0.77 |
MTX use (n, %) | 4/10, 40% | 6/10, 60% | 4/10, 40% | 10/10, 100% | 0.03* |
MTX dose (mg/week) | 7.5 (4.1) | 8.3 (2.0) | 4.4 (0.9) | 9.0 (3.6) | 0.07 |
CRP (mg/dl) | 0.01 (0.02) | 0.01 (0.02) | 0.03 (0.03) | 0.13 (0.10) | <0.01* |
ESR (mm/h) | 6.0 (4.7) | 6.6 (5.6) | 12.3 (14.4) | 22.2 (12.8) | <0.01* |
CDAI | 5.2 (1.3-8.1) | 1.7 (0.1-7.9) | 1.7 (0.1-5.8) | 3.6 (0.2-6.3) | 0.07 |
HAQ-DI | 1.1 (0.8) | 0.5 (0.6) | 0.3 (0.5) | 0.5 (0.5) | 0.06 |